Technology
Benitec Biopharma Reports Positive Data from Two Subjects Treated with Low-Dose BB-301 in Phase 1b/2a Study Presented at 29th Annual Congress of the World Muscle Society
By: investing_za
- Oct 12 2024
- 0
- 0 Views
ONLY AVAILABLE IN PAID PLANS